Trial · NCT04347031
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1st primary endpoint for group 1 | up to 10 days | The number of patients with development of respiratory failure requiring transfer to the ICU. |
| Primary | 2nd primary endpoint for group 1 | up to 10 days | The period of clinical recovery. |
| Primary | 1st primary endpoint for group 2 | up to 10 days | The period of clinical recovery. |
| Primary | 2nd primary endpoint for group 2 | through study completion, an average of 3 months | Frequency of fatal outcomes associated with coronavirus infection disease (COVID19) |
| Secondary | 1st secondary endpoint for group 1 | on days 5 and 10 | A change in viral load by conducting PCR assay through different timeframes |
| Secondary | 2nd secondary endpoint for group 1 | on day 10 | Frequency of clinical cure on day 10 from the start of therapy |
| Secondary | 3d secondary endpoint for group 1 | up to 10 days | The retention time of the reaction temperature from the start of the treatment. |
| Secondary | 4th secondary endpoint for group 1 | up to 10 days | Concentration of C-reactive protein in blood plasma. |
| Secondary | 5th secondary endpoint for group 1 | up to 10 days | Respiratory index. |
| Secondary | 6th secondary endpoint for group 1 | up to 10 days | Frequency appearance unwanted phenomena and serious unwanted phenomena |
| Secondary | 1st secondary endpoint for group 2 | on days 5 and 10 | A change in viral load by conducting PCR assay through different timeframes |
| Secondary | 2nd secondary endpoint for group 2 | up to 10 days | Respiratory index. |
| Secondary | 3d secondary endpoint for group 2 | up to 10 days | The retention time of the reaction temperature from the start of treatment. |
| Secondary | 4th secondary endpoint for group 2 | up to 10 days | Concentration of C-reactive protein in blood plasma. |
| Secondary | 5th secondary endpoint for group 2 | up to 10 days | Number of patients required transition to alternative therapy schedule |
| Secondary | 6th secondary endpoint for group 2 | up to 10 days | Frequency of adverse events and serious adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04347031/registered